Physician profile
Michelle Man
NPI 1336528603
$20,346.39
in general payments reported to CMS, 2019-2025
20 companies · $7,638 in 2025
The $7,638 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $249 · 2021: $1,072 · 2022: $226 · 2023: $3,438 · 2024: $6,717 · 2025: $7,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,750 · Food and Beverage: $4,108 · Travel and Lodging: $3,036 · Gift: $2,275 · Consulting Fee: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,750.00 |
| Food and Beverage | $4,107.83 |
| Travel and Lodging | $3,035.84 |
| Gift | $2,275.00 |
| Consulting Fee | $625.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $11,018.95 | 2019-2025 | Misight Contact Lens, Ortho-K Contact Lens, Clariti Contact Lens |
| Visionary Optics LLC | $2,850.21 | 2023-2024 | |
| Johnson & Johnson Vision Care, INC. | $1,375.18 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,254.75 | 2019-2025 | Air Optix, Rocklatan, Simbrinza |
| Allergan, INC. | $943.00 | 2019-2021 | |
| Rxsight INC | $822.40 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $532.20 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $278.95 | 2020-2023 | Cequa |
| Abbvie INC. | $162.10 | 2023-2024 | |
| Glaukos Corporation | $158.98 | 2024 | Ce-Marked Kxla System |
| Tarsus Pharmaceuticals, INC. | $156.00 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $126.42 | 2019-2020 | |
| Amgen INC. | $124.26 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $122.70 | 2021 | |
| Oyster Point Pharma, INC. | $119.48 | 2023-2024 | Tyrvaya, Ryzumvi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $103.60 | 2019 | |
| Thea Pharma INC. | $91.48 | 2023 | |
| Novartis Pharmaceuticals Corporation | $45.15 | 2020-2023 | |
| Harrow Eye, LLC | $42.42 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $18.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Man listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.